filmov
tv
MRD Testing in Hematologic Malignancies
Показать описание
OncLive
cancer
oncology
Рекомендации по теме
0:03:31
MRD Testing in Hematologic Malignancies
0:05:27
MRD Testing in Hematologic Malignancies Other Than ALL
0:01:37
Assessing MRD in hematologic malignancies
0:34:46
Game-Changing Potential of MRD in Hematological Malignancies: Overview and Importance
0:41:50
MRD Testing in Blood Cancers: Latest Advances | Dr. Noopur Raje | CME Activity
0:34:46
AMP 2016 MRD Solutions for the Studies of Hematologic Malignancies – LymphoTrack® Assays
0:00:57
Dr. Daver Discusses Use of MRD Assessment in Hematologic Malignancies
0:22:56
Measurable Residual Disease (MRD) in AML and ALL
0:19:41
Multiple Myeloma: Minimal Residual Disease
0:31:31
MRD in Acute Myeloid Leukemia
0:28:37
Acute Lymphocytic Leukemia: Overview of Latest Guidelines in Hematological Malignancies
0:26:34
Chronic Lymphocytic Leukemia: MRD Updates
0:10:49
AMP 2016 MRD Solutions for the Studies of Hematologic Malignancies – FLT3 ITD MRD
0:00:31
Advanced NGS Methods for Molecular Testing of Hematological Malignancies
0:02:03
Updated FDA MRD guidelines for hematological malignancies
0:02:35
An update on MRD assessment and novel techniques used in the treatment of hematological malignancies
0:18:50
MRD Detection, Single Cell RNA Seq., Cell Free DNA, etc: Does it Impact Treatment?
0:07:39
Understanding MRD
0:21:09
Minimal residual disease (MRD) in CLL: Is it clinically relevant?
0:05:49
Is minimal residual disease (MRD) testing routinely recommended?
0:02:36
MRD testing in AML: the next steps in 2019
0:01:00
Dr. Radich on the Evolving Role of MRD in Hematologic Malignancies
0:01:00
The potential use of multi-gene molecular MRD testing in AML
0:24:14
Current AML landscape: Where do we stand in 2018?
0:03:31
0:05:27
0:01:37
0:34:46
0:41:50
0:34:46
0:00:57
0:22:56
0:19:41
0:31:31
0:28:37
0:26:34
0:10:49
0:00:31
0:02:03
0:02:35
0:18:50
0:07:39
0:21:09
0:05:49
0:02:36
0:01:00
0:01:00
0:24:14